Assistant Professor of Pharmacology
Bio
Dr. Horiuchi arrived at Northwestern University Feinberg School of Medicine in 2015, and is a member of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center. He received his doctorate from Indiana University in cell and molecular biology. Dr. Horiuchi conducted his postdoctoral fellowship at University of California, San Francisco, where he was a member of the Breast Cancer Oncology Program within UCSF Helen Diller Family Comprehensive Cancer Center.
Dr. Dai Horiuchi’s ongoing breast cancer research is geared toward identifying new therapeutic strategies for triple-negative breast cancer (TNBC). Triple-negative tumors are the breast cancer subtype with the poorest clinical outcome, presenting serious challenges for patients and researchers. Dr. Horiuchi investigates tumor generation and progression, as well as validating novel and safer therapies.
As a Lynn Sage Scholar, Dr. Horiuchi is studying a family of proteins as an immuno-oncology target for TNBC tumors. His laboratory utilizes bioinformatics, sophisticated screening strategies, and collaborations with clinicians and pharmaceutical partners. He is dedicated to bringing his laboratory findings to clinical testing in order to significantly reduce TNBC-related mortality.
Dai Horiuchi, PhD
Northwestern University Feinberg School of Medicine
Newly funded researchers pursuing high-risk, high-reward breast cancer studies in their first or second academic positions.
Past
Early Investigator
Abde Abukhdeir, PhD
The molecular variants that lead or contribute to drug resistance in breast cancer
Past
Early Investigator
Nan Chen, MD
Discovering novel biomarkers of therapy response and resistance in metastatic triple-negative breast cancer patients
Past
Early Investigator
Peiwen Chen, PhD
Targeting macrophage reprogramming in brain metastatic breast cancer
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
